Document:

EX-10.11

 Exhibit 10.11 

Certain identified information has been marked in the exhibit because it is both (i) not material and (ii) would likely cause
competitive harm to the Company, if publicly disclosed. Double asterisks denote omissions. 
 INOZYME PHARMA, INC. CONFIDENTIAL 

YALE UNIVERSITY 

CORPORATE SPONSORED RESEARCH AGREEMENT 

This RESEARCH AGREEMENT (this “Agreement”) is entered into as of January 6, 2017 (the “Effective
Date”), by and between Yale University, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of
Connecticut (the “University”), and Inozyme Pharma, LLC, a Delaware limited liability company, having its principal offices at [**] (the “Sponsor”). 

W I T N E S S E T H : 
 WHEREAS,
in pursuit of its educational purposes, which include research and training, the University undertakes scholarly, research, and experimental activities in a variety of academic disciplines including the biology of the modulation of inorganic
pyrophosphate and calcification by ectonucleotide pyrophosphatase/phosphodiesterases (“ENPPs”); and 
 WHEREAS, the
Sponsor wishes to fund and desires that the University undertake a research program in the field of ENPPs, as described more fully in Exhibit A, attached hereto; and 

WHEREAS, in furtherance of its scholarly, research, and instructional interests, the University is willing to undertake such research upon the
terms and conditions set forth below; and 

 NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained,
the parties hereto agree as follows: 
 1.    Scope of Research. During the term of this
Agreement, the University shall use reasonable efforts to perform the research program described in Exhibit A, attached hereto and incorporated herein (the “Research”) using the levels of diligence, care and skill applicable
to academic research typically conducted at the University. Notwithstanding the foregoing, the University makes no warranties or representations regarding its ability to achieve, nor shall it be bound hereby to accomplish, any particular research
objective or results. 
 2.    Personnel. 

(a)    The Research shall be performed by and under the supervision and direction of Dr. Demetrios Braddock, while
employed by the University, who shall be designated the Principal Investigator (the “Principal Investigator”) together with such additional personnel as may be assigned by the University and who are employees or agents of the
University. If Dr. Braddock ceases to be available to act as Principal Investigator, the University shall give Sponsor written notice of any proposed change in the Principal Investigator, subject to Sponsor’s approval, which the Sponsor
may withhold in its sole discretion. In case a replacement Principal Investigator cannot be found who is acceptable to the University and the Sponsor, then the Sponsor may terminate the Term (as defined herein) on 30 days’ notice to the
University. 
 (b)    It is understood that the University and the personnel performing the Research hereunder may be
involved in other activities and projects which entail pre-existing commitments to other sponsors. The University will use reasonable efforts to avoid conflicts with the terms of this Agreement; however, it is
agreed that unless provided to the contrary herein, this Agreement is subject to the University’s pre-existing commitments to such other sponsors. [**]. 

  
 2 

 3.    University Policies and Procedures.
All Research conducted hereunder shall be performed in accordance with established University policies and procedures, including, but not limited to, policies and procedures applicable to research involving human subjects, laboratory animals,
and conflicts of interest. 
 4.    Reimbursement of Costs. 

(a)    The Sponsor shall reimburse the University for all direct and indirect costs incurred by the University in
connection with the Research, in accordance with the budget set forth as Exhibit B, in the amount of [**] Dollars ($[**]), attached hereto and which hereby is incorporated herein; provided, however, that the University may submit to Sponsor at any
time, and Sponsor may at its discretion approve in writing, a revised budget or budgets requesting additional funds. Indirect costs shall be equal to the facilities and administration rate for indirect costs negotiated between the University and the
Federal Government. 
 (b)    The Sponsor shall make quarterly advance payments to the University to fund estimated
reimbursable costs, as determined in advance by Yale in good faith, it being understood that Yale’s estimate is not a guarantee of actual reimbursable costs for the applicable quarter. All checks shall be made payable to Yale University, shall
include reference to the Principal Investigator, and shall be sent to: 
 Yale University 

Office of Sponsored Projects 
 P.O.
Box 1873 
 New Haven, CT 06508-1873 

Contacting email: [**] 
 Or wired
to: 
 [**] 
 Reference:
Demetrios Braddock, Principal Investigator; [**] 

  
 3 

 5.    Research Reports. The University shall
furnish to Sponsor during the term of this Agreement periodic informal reports regarding the progress of the Research. A final report setting forth the significant research findings shall be prepared by the University and submitted to Sponsor within
a reasonable period following the expiration of the Term or the effective date of early termination. The University shall hold such reports in confidence subject to its rights under Section 6. The Sponsor shall hold such reports in confidence
pursuant to Section 7. 
 6.    Publication. 

(a)    Part of the University’s mission is to publish and disseminate research results developed under sponsored
research projects. Consistent with this Agreement, University, the Principal Investigator and other University employees and/or students may disseminate or publish the results of the Research without prior approval by the Sponsor. The University
shall provide the Sponsor with a copy of any proposed publication 45 days in advance of submission to third parties. The Sponsor shall determine whether any of its Confidential Information is included in the proposed publication. The Sponsor may
reasonably require that any of its Confidential Information be removed from the proposed publication. The Sponsor may reasonably require that submission of the proposed publication to third parties and publication be W I delayed to permit the filing
of patent applications. The Sponsor shall make such determinations within forty-five (45) days of receipt of the proposed publication. Submission of the proposed publication shall not be delayed more than ninety (90) days after receipt of
the proposed publication by the Sponsor. The Sponsor at its election shall be entitled to receive an acknowledgment of its sponsorship of the Research in any such publication. 

  
 4 

 (b)    The University shall have the final authority to determine the
scope and content of any publications or presentations made by its students and employees in accordance with the limitations of this section. 

7.    Confidential Information. 

(a)    Confidential Information consists of information that has been reduced to writing and marked
“Confidential,” or, if disclosed orally, has been reduced to writing and marked “Confidential” within [**] of oral disclosure. Subject to the following exceptions, all Confidential Information of either party disclosed by or on
behalf of it to the other party in connection with the Research hereunder will be treated by such other party as confidential throughout the term hereof or for [**] from the time of disclosure, whichever is longer. Each party will use reasonable
efforts to safeguard the confidentiality of the other Party’s Confidential Information, and will require its employees, agents, students and associates to adhere to such obligation of confidentiality. The following shall be exceptions to
confidentiality: 
 (i)    Information that is now in the public domain or subsequently enters the public domain through
no fault of the receiving party; 
 (ii)    Information that is presently known or becomes known to the receiving party
from its own independent sources; 
 (iii)    Information that the receiving party receives from any third party not
under any obligation to keep such information confidential; 
 (iv)    Information that is required to be disclosed by
law. 
 (v)    Information that is developed independently by persons who had no direct or indirect access to the
information. 
 Neither party will use any Confidential Information of the other party provided under this Agreement for any purpose other than carrying out
the Research and performing the parties’ respective obligations under this Agreement. 

  
 5 

 (b)    Neither party shall knowingly convey Confidential Information
that is subject to federal export control restrictions under the EAR or the ITAR without first so disclosing to the other party and providing the other party the opportunity to decline receiving such information. 

(c)    Notwithstanding the foregoing in this Article 7, the Sponsor may disclose or release the results of the Research in
connection with obtaining necessary regulatory approvals by a governmental authority for any ENPP product or ENPP product candidate of the Sponsor that is the subject of any license agreement between the University and the Sponsor pertaining, in
part or in whole to such ENPP products or ENPP product candidates (a “Regulatory Disclosure”) to the extent that such Regulatory Disclosure is necessary or appropriate in the Sponsor’s judgment to obtain such approvals
[**]. 
 (d)    [**] under this Section 7. 

8.    Intellectual Property. 

(a)    Definition of Invention. “Invention” shall mean any discovery, concept or idea,
whether or not patentable, first conceived, discovered or first reduced to practice in whole or in part in performance of this Agreement. For purposes of this Agreement, “Invention” shall also include any software written, created, and
utilized in performance of this Agreement. 
 (b)    Ownership of Inventions. The University shall be entitled to
ownership of any Invention first conceived or discovered solely by its employees, students, or agents in the performance of the Research (“University Inventions”). Sponsor shall own any Inventions first conceived or
discovered solely by Sponsor’s employees or agents (“Sponsor Inventions”). Inventions first conceived or discovered jointly by University employees, students or agents and Sponsor employees or agents in the performance
of the Research shall be owned jointly (“Joint Inventions”). 

  
 6 

 (c)    Disclosure and Right to Patent Inventions. The University
and Sponsor shall promptly disclose to each other in writing any Invention first conceived or discovered in the performance of the Research [**], and reported to the University’s Office of Co-operative
Research (“OCR”) if a University Invention or Joint Invention or Sponsor’s Intellectual Property Authority (“IPA”) if the Invention is a Joint Invention (see Article 11 “Notices”), respectively. Such
disclosure shall be considered Confidential Information. The University may elect to file and prosecute a patent application on any University Invention described in any such Invention disclosure. Should the University elect not to do so it will so
notify the Sponsor and the Sponsor may at its own cost file and prosecute any such patent application on behalf of the University. The Sponsor shall have the sole right to file and prosecute a patent application on any Sponsor Invention and Joint
Invention. If Sponsor elects not to file or to prosecute an application for a Joint Invention or if after filing such an application, Sponsor elects not to prosecute such application, then in any such case Sponsor shall notify the University
promptly and, if University elects to file and prosecute such an application on a Joint Invention, Sponsor shall not grant rights to such Joint Invention to any third party without University’s prior written permission. [**]. 

(d)    [**] & Option. 
  

	 	i.	 [**], the Sponsor shall have [**]; provided, however, that [**]. 

 

	 	ii.	 Option. For each University Invention or University’s interest in a Joint Invention that, at the
time the University makes written disclosure thereof to the Sponsor, [**], the Sponsor will have the option, for a period of three (3) months from the date of such disclosure to Sponsor, to elect to negotiate for a royalty-bearing, exclusive or
non-exclusive, world-wide license to 

  
 7 

	 	
University’s rights in such Invention, including the right to sublicense, to make, have made, use, lease, sell, import and export products embodying or produced through the use of such
Invention (the “Option”). In the event that the parties are unable to reach agreement on the terms of the license described above in this Section 8(d)(ii) for such Invention after three (3) months of good faith
negotiations, and the parties therefore do not execute such license, the University may enter into an agreement relating to such Invention with any third party [**]. 

(e)    New License. Any license to Sponsor as provided herein [**] will be granted by a separate license agreement
signed by the parties which shall include at least the following terms and conditions: (a) an appropriate field of use; (b) mutually agreeable license fees and royalties; (c) mutually agreeable minimum royalties and/or other
requirements of due diligence to develop and effectively commercialize the Invention; (d) reimbursement of University’s cost of patent filing, prosecution and maintenance; (e) retention by University of a royalty-free right,
sublicensable to its research partners, to use the Invention for teaching, research, or other educational or academic purposes; and (f) indemnification of the University. 

(f)    Data. University will retain ownership of the data arising out of the Research that University generates.
Subject to other provisions of this Agreement, including those pertaining to Confidential Information and intellectual property, Sponsor will have access to the data and may use such data in connection with its internal research, subject to the
applicable confidentiality provisions of this Agreement. 
 (g)    Tangible Research Property. University shall
retain ownership of property that is developed solely by University’s employees, students, and agents, including, but not limited 

  
 8 

 
to, prototypes, biogenic materials, samples, lab notebooks graphs, maps, drawings, and documents created or acquired under this Agreement (collectively, “Tangible Research
Property”), except the University shall not retain ownership of any such Tangible Research Property that is a deliverable under this Agreement. [**]. University shall retain the right to use and distribute copies of all deliverables for
educational and/or research purposes. 
 (h)    Copyrightable material. As between University and Sponsor,
University shall own all right, title and interest in and to any and all copyrights and copyrightable materials, including data and excluding software, that is created solely by University employees, students or agents in performance of this
Agreement (collectively “University Copyrights”). As between University and Sponsor, Sponsor shall own all right, title and interest in and to any and all copyrights and copyrightable materials, including data, created solely
by Sponsor employees or agents in performance of this Agreement (collectively, “Sponsor Copyrights”). As between University and Sponsor, University and Sponsor shall jointly own all right, title and interest in and to any and all
copyrights and copyrightable materials, including data, created jointly by University employees, students, or agents and Sponsor employees or agents in performance of this Agreement (collectively, “Joint Copyrights”).
University shall have the sole right to determine the disposition of University Copyrights, provided that Sponsor shall have option rights, in accordance with Section 8, in computer software and databases developed and delivered under the
Statement of Work. 
 (i)    Background IP. Neither party shall, by virtue of this Agreement, acquire rights to
Inventions, copyrights, technical information, or tangible property concurrently created or acquired outside of this Agreement or that are owned by the other party prior to entering into this Agreement, including any background technology required
to practice Inventions. Such rights may or may not be available for licensing. 

  
 9 

 9.    Ownership of Property. Title to any
equipment purchased or created in the performance of the work funded under this Agreement shall vest in the University. 

10.    Term and Termination. 

(a)    This Agreement shall be effective for the term January 6, 2017 through January 6, 2020 (the
“Term”), and may be extended thereafter by mutual agreement of the parties in writing; provided, however, that the termination of this Agreement shall not relieve either party of any obligation of such party accrued prior to
such termination hereunder. In particular, the provisions hereof relating to rights in patents and ownership of property shall survive such termination. 

(b)    Notwithstanding the foregoing, this Agreement may be terminated by either party at any time upon 180 days advance
written notice to the other party; provided, however, that Sponsor may also terminate this Agreement pursuant to Section 2(a). Upon receipt of notice of early termination by Sponsor, the University shall use reasonable efforts promptly
to limit or terminate any outstanding commitments prior to the effective termination date. All allowable costs associated with such termination and up through the date of termination, shall be reimbursed by Sponsor, including non-cancelable commitments, such as, where applicable, committed salary and benefits [**] for personnel shall be non-cancelable commitments. In case of such termination, such
amounts for such non-cancellable obligations shall be the limits of the Sponsor’s liability for payments to the University hereunder. 

(c)    If Sponsor breaches its obligation of payment and fails to remedy such breach within thirty (30) days after
receipt of notice in writing of such breach, then if such payment 

  
 10 

 
breach is not remedied in such thirty (30) day period, the University may, in addition to any other remedies that the University may have at law or in equity, terminate this Agreement by
sending written notice of termination to Sponsor. Termination for material breaches will be effective from the date of notice to Sponsor and does not affect any of University’s other rights under this Agreement. 

11.    Notices. Any notices given under this Agreement shall be in writing and shall be deemed
delivered when sent by first-class mail, postage prepaid, addressed to the parties as follows (or at such other addresses as the parties may notify each other in writing): 
  

			
	 The University
  

Yale University
 Office of Sponsored Projects (OSP)

25 Science Park - 3rd Floor
 P.O. Box 208327

New Haven, CT 06520-88327
 ATTN: [**]

Contract Manager
	  	 Sponsor
  

Inozyme Pharma, LLC
 [**]

ATTN: Chief Executive Officer
 [**]

	  
 Yale University

Office of Cooperative Research
 433 Temple Street
	  	
	 New Haven, CT 06511
 ATTN: Managing
Director
	  	[**]

 provided, however, that Invention Disclosures shall be addressed to the parties as follows: 

 

			
	 Yale University
  

Yale University Office of Cooperative Research
 Attn: Director of
Intellectual Property
 433 Temple Street
 New Haven, CT,
06511
 P: [**]
 E: [**]

CC: [**]
	  	 Sponsor IPA
  

[**]

  
 11 

 12.    Use of Name. Neither party shall
employ or use the name of the other party in any promotional materials or advertising without the prior express written permission of the other party. 

13.    Relationship of the Parties. The relationship of Sponsor and the University established
by this Agreement is that of independent contractors. Nothing in this Agreement shall be construed to create a relationship of employment or agency, nor shall either party’s employees, servants, agents, or representatives be considered the
employees, servants, agents, or representatives of the other. Nothing in this Agreement shall be construed to constitute the parties as partners or joint venturers, or allow either of the parties to create or assume any obligation on behalf of the
other party. 
 14.    Indemnification. The following indemnification obligation applies
only to the extent of Sponsor’s use of the Research or any University intellectual property or Research Results. The Sponsor shall therefore defend, indemnify and hold harmless University, the Principal Investigator, in his capacity as such,
and any of University’s faculty, students, employees, trustees, officers, affiliates, and agents (hereinafter referred to collectively as the if “Indemnified Persons”) from and against any and all liability, claims,
lawsuits, losses, damages, costs or expenses (including attorneys’ fees), which the Indemnified Persons may hereafter incur, or be required to pay, unless determined with finality by a court of competent jurisdiction to result solely from an
Indemnified Person’s gross negligence or willful misconduct. University shall notify Sponsor upon learning of the institution or threatened institution of any such liability, claims, lawsuits, losses, damages, costs and expenses and University
shall cooperate with Sponsor in every proper way in the defense or settlement thereof at Sponsor’s request and expense. Sponsor shall not dispose or settle any claim admitting liability on the part of the University without University’s
prior written consent. 

  
 12 

 15.    NO WARRANTIES. THE UNIVERSITY MAKES
NO WARRANTIES EITHER EXPRESS OR IMPLIED, AS TO ANY MATTER, INCLUDING, WITHOUT LIMITATION, THE RESULTS OF THE RESEARCH OR ANY INVENTIONS OR PRODUCT, TANGIBLE OR INTANGIBLE, CONCEIVED, DISCOVERED, OR DEVELOPED UNDER THIS AGREEMENT; OR THE OWNERSHIP,
MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE RESEARCH RESULTS OR OF ANY SUCH INVENTION OR PRODUCT. Neither party shall be liable for any indirect, consequential, lost profits, or other damages suffered by the other party or by any
Licensee or any others resulting from the use of the research results, including any Invention, program, or product. 

16.    Export Controls. The University complies with all applicable laws and, regulations,
including, where applicable, federal export control regulations. Many of the University employees (faculty and staff) and students are residents of foreign countries, including individuals who may work on this contract and/or have access to
information conveyed to the University pursuant hereto. The University does not screen its employees or students based on nationality. In most situations, the University relies on the fundamental research exclusion from export control laws, but
makes no representation as to whether Sponsor’s conveyance of information or material to the University pursuant hereto would be covered by the export control laws. Each party agrees that before knowingly providing the other with
export-controlled materials or data, it will provide written notice, including a description of the materials or data, and, if known, the appropriate ECCN or MCL designation. No such materials or data shall knowingly be shared without prior written
approval. 

  
 13 

 17.    Force Majeure. The University shall
not be liable for any failure to perform as required by this Agreement, to the extent such failure to perform is caused by any reason beyond the University’s control, or by reason of any of the following: labor disturbances or disputes of any
kind, accidents, failure of any required governmental approval, civil disorders, acts of aggression, acts of God, energy or other conservation measures, failure of utilities, mechanical breakdowns, material shortages, disease, or similar
occurrences. 
 18.    Assignment. Neither the University nor the Sponsor shall assign this
Agreement to any other person without the prior written consent of the other, and any purported assignment without such consent shall be void [**]. 

19.    Severability. In the event that a court of competent jurisdiction holds any provision
of this Agreement to be invalid, such holding shall have no effect on the remaining provisions of this Agreement, and they shall continue in full force and effect. 

20.    Entire Agreement: Amendments. This Agreement and the Exhibits hereto contain the entire
agreement between the parties. No amendments or modifications to this Agreement shall be effective unless made in writing and signed by authorized representatives of both parties. 

21.    Similar Research. Nothing in this Agreement shall be construed to limit the freedom of
the University or of its researchers who are not participants under this Agreement, from engaging in similar research made under other grants, contracts or agreements with parties other than the Sponsor. 

  
 14 

 22.    Governing Law. This Agreement shall
be governed by and construed in accordance with the laws of the State of Connecticut. 
 IN WITNESS WHEREOF, the parties hereto have
executed this Agreement by their duly authorized officers or representatives. 
  

			
	 YALE UNIVERSITY
  

By /s/ Jeffrey E.
McGuinness                            

 
 Title  Associate
Director                                    

 
 Date  January 10,
2017                                      
	  	 INOZYME PHARMA, LLC
  

By /s/ Axel
Bolte                                    

 
 Title  Chief Executive
Officer                
  

Date  January 10,
2017                          

 Read and acknowledged: 

Principal Investigator 
  

	
	
	 /s/ Demetrios Braddock

Demetrios Braddock, MD PhD

 

Date  01/09/2017               
                                         
                

  
 15 

 Exhibit B: Budget 
  

																	
	 	  	Year 1	 	 	Year 2	 	 	Year 3	 	 	Total	 
	 YALE TOTAL DIRECT COSTS - Grant
	  	$	[	**] 	 	$	[	**] 	 	$	[	**] 	 	 	[	**] 
	 Total Indirects
	  	$	[	**] 	 	$	[	**] 	 	$	[	**] 	 	 	[	**] 
	 Total Grant Budget
	  	$	[	**] 	 	$	[	**] 	 	$	[	**] 	 	 	[	**] 

  
 16 

 YALE UNIVERSITY 

AMENDMENT NO. 1 TO 

CORPORATE SPONSORED RESEARCH AGREEMENT 

This AMENDMENT NO. 1 TO CORPORATE SPONSORED RESEARCH AGREEMENT, dated as of February 19, 2019 (this “Amendment”),
by and between Yale University, a non-profit corporation organized and existing under and by virtue of a special charter granted by the General Assembly of the Colony and State of Connecticut (the
“University”), and Inozyme Pharma, Inc., a Delaware corporation, having its principal offices at 280 Summer Street, Floor 5, Boston, Massachusetts 02210 (the “Sponsor”), amends the RESEARCH
AGREEMENT, entered into as of January 6, 2017 (the “Agreement”), by and between the University and the Sponsor. 

W I T N E S S E T H: 

WHEREAS, the Sponsor has funded a research program in the field of ENPPS. 

WHEREAS, the Sponsor now wishes to continue to fund for an extended period (years 3-5) research
programs in the field of expertise of the Principal Investigator, as described more fully in Exhibit A, attached to this Amendment; and 

WHEREAS, the Sponsor wishes to allow for a broader research program and to amend the the budget for the research to take place during
the Extended Term (as defined herein) as provided in the Agreement, and the University is willing to agree to such modifications and to undertake such research upon the terms and conditions set forth below and in the Agreement; 

NOW, THEREFORE, in consideration of the premises and the mutual covenants herein contained, the parties hereto agree as follows:

 1.    Scope of Research. Upon the effectiveness of this Amendment, the Agreement is hereby
amended such that during the Extended Term, the University shall use reasonable efforts to perform the research program described in Exhibit A, attached hereto and incorporated herein and incorporated in the Agreement to allow for
expansion of the original Research, and otherwise in accordance with the terms and limitations provided in the Agreement. The Research provided for in this Amendment shall be in lieu of the portion of the Research for the third year of the Term as
provided in the Agreement and shall also extend for the Extended Term. Any additional research requested by Sponsor that is supplemental to the research 

 
selected by the Principal Investigator – relating to ENPPs within the amended program described in Exhibit A attached hereto, shall be the subject of a separately negotiated financial
agreement between the University and Sponsor. 
 2.    Reimbursement of Costs. The Agreement is
hereby amended such that the Sponsor shall reimburse the University for all direct and indirect costs incurred by the University in connection with the Extended Research, in accordance with the budget set forth as Exhibit B
hereto (the “Extended Budget”), in the amount of [**] Dollars ($[**]), attached hereto and which hereby is incorporated herein and incorporated in the Agreement. The first year of the Extended Budget shall be in
lieu of $[**] of Total Grant Budget for Year 3 as shown in the budget attached as Exhibit B to the Agreement. Nothing in this Amendment modifies the Total Grant Budget shown for each of Year 1 and Year 2 in the Agreement. Once the parties execute
and deliver this Amendment, the Total Grant Budget and Extended Budget under the Agreement, as amended by this Amendment, will be: 
  

					
	 Year 1
	  	 	$[**]	 
	 Year 2
	  	 	$[**]	 
	 Year 3
	  	 	$[**]	 
	 Year 4
	  	 	$[**]	 
	 Year 5
	  	 	$[**]	 
		  	  
	  
	 
	 Total
	  	$	2,409,708	 
		  	  
	  
	 

 Indirect costs for the Extended Budget shall be as shown in the Extended Budget. 

3.    Amendment to Term. The first sentence of Section 10(a) of the Agreement is hereby amended
by deleting the words “January 6, 2020” and substituting in lieu thereof “December 31, 2021”. The period of the New Research shall be referred to as the “Extended Term.” 

4.    Defined Terms. Capitalized terms used in this Amendment and defined in the introductory
paragraph of, or recitals to, this Amendment shall have the respective meanings provided therein. Capitalized terms used in this Amendment and not defined in this Amendment shall have the respective meanings provided in the Agreement except as
otherwise expressly provided herein. 

  
 2 

 5.    Effectiveness. This Amendment shall become
effective as of the date first set forth above once this Amendment or counterparts hereof shall have been executed and delivered by University and the Sponsor. 

6.    Confirmation of Original Agreement. 

 

	 	(a)	 Except as amended by this Amendment, the Agreement shall remain in füll force and effect in accordance
with its terms. From and after the date this Amendment becomes effective, any reference in the Agreement to the “Agreement”, the “Research” or the “Term” shall be deemed a reference to the Agreement, as amended hereby,
the Research, as defined hereby, or the Extended Term, as defined hereby, respectively. 

7.    Governing Law. This Amendment shall be governed by and construed in accordance with the laws of
the State of Connecticut. 
 [signature page follows] 

  
 3 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement by their duly authorized
officers or representatives. 
  

											
	 YALE UNIVERSITY
	 		 	 INOZYME PHARMA, INC.
	 	
						
	By	 	 /s/ James Cresswell
	 		 	By	 	 /s/ Henric Bjarke
	 	
						
	Title	 	 Sr. Contract Manager
	 		 	Title	 	 COO
	 	
						
	Date:	 	February 19, 2019	 		 	Date:	 	2/22/2019	 	

  

							
	Read and acknowledged:	  		 		 	
				
	Principal Investigator	  		 		 	
				
	 /s/ Demetrios Braddock
	  		 		 	
	Demetrios Braddock, MD PhD	  		 		 	
				
	Date:  February 19th, 2019        	  		 		 	

  
 4 

 Exhibit B: Extended Budget 

Amendment No. 1 to Corporate Sponsored Research Agreement 
  

									
	 	  	Year 3	 	Year 4	 	Year 5	 	Total
					
	 Total Direct Costs
	  	[**]	 	[**]	 	[**]	 	[**]
					
	 Indirect Rage
	  	[**]	 	[**]	 	[**]	 	[**]
					
	 Total Indirect Costs
	  	[**]	 	[**]	 	[**]	 	[**]
					
	 Total Grant Budget
	  	[**]	 	[**]	 	[**]	 	[**]

  
 5EX-10.12

 Exhibit 10.12 

INOZYME PHARMA, LLC 

RESTRICTED STOCK AGREEMENT 

THIS RESTRICTED STOCK AGREEMENT, dated as of the date set forth on Exhibit A hereto (this “Agreement”), by and between
Inozyme Pharma, LLC, a Delaware limited liability company (the “Company”), and the person named in Exhibit A hereto (the “Purchaser”). 

W I T N E S S E T H: 

WHEREAS, the Company wishes to sell, and the Purchaser wishes to purchase, shares of Class 1 Stock (as hereinafter defined) in the
Company as shown on Exhibit A hereto; and 
 WHEREAS, the Company is offering to sell such shares to the Purchaser as part of
the consideration for the Purchaser serving in the office(s) or position(s), if any, shown on Exhibit A hereto; and 
 WHEREAS,
the Company and the Purchaser wish to set forth certain agreements concerning restrictions on the Purchaser’s rights with respect to such shares; 

NOW THEREFORE, in consideration of the premises and the mutual covenants herein set forth, and other good and valuable consideration,
the receipt and sufficiency of which are hereby acknowledged, the Company and the Purchaser agree as follows: 

1.    Purchase and Sale of Shares; Closing. 

(a)    Upon the terms and subject to the conditions of this Agreement, the Company hereby agrees to sell to the Purchaser,
and the Purchaser hereby agrees to purchase from the Company, on the Closing Date (as hereinafter defined), the number of shares of Class 1 Stock of the Company (the “Class 1 Stock”) shown on Exhibit A hereto (the
“Shares”) for the aggregate purchase price shown on Exhibit A hereto (the “Purchase Price”) and for the other consideration, if any, stated on Exhibit A hereto. The Purchaser shall pay the Purchase Price for the
Shares by check or in cash. The attached Exhibits form part of this Agreement. 
 (b)    The purchase and sale of the
Shares shall occur at a closing (the “Closing”) to be held at such time as shall be designated by the Company (the “Closing Date”) by at least two days’ notice to the Purchaser. The Closing will be held at the office of the
Company’s legal counsel shown on Exhibit A hereto or at such other place as shall be designated by the Company. At the Closing, the Purchaser shall: 

(1)    execute and deliver to the Company a counterpart of the Limited Liability Company Agreement of Inozyme Pharma,
LLC, dated as of September 11, 2015 (as amended from time to time, the “LLC Agreement”); 

(2)    execute and deliver to the Company and the other parties thereto a counterpart of the Stockholders Agreement,
dated as of September 11, 2015 (as amended from time to time, the “Stockholders Agreement”); 

 (3)    execute and deliver to the Company a counterpart of the
Registration Rights Agreement, dated as of September 11, 2015 (the “Registration Rights Agreement”); and 

(4)    deliver to the Company a check payable to the order of the Company or cash in the amount of the Purchase Price.

 As promptly as practicable thereafter, the Company shall amend the Stockholders Ledger (as defined in the LLC Agreement), to reflect the admission of the
Purchaser as a Member holding the number of Shares purchased hereunder. 
 2.    Purchase Option. 

(a)    (1)     As set forth in Exhibit A hereto, a portion of the Shares shall be subject to the
right and option of certain other persons who are Members holding shares of Class 1 Stock of the Company and who are named in Exhibit A hereto (the “Purchase Right Members”) to purchase such portion of the Shares (the
“Member Purchase Option”) and, if no Purchase Right Member exercises his Member Purchase Option or if Purchase Right Members exercise the Member Purchase Option for fewer than all the Shares subject thereto, to the right and option of the
Company to purchase the available amount of such Shares (the “Company Purchase Option”), all as set forth in this Section 2. The Purchaser hereby grants the Purchase Right Members the right to exercise the Member Purchase Option if a
“Purchase Event” as defined in Exhibit A hereto shall occur (the “Purchase Event”). 

(2)    If the Purchase Right Members do not exercise the Member Purchase Option for all Shares subject to the Member
Purchase Option, then the Purchaser hereby grants the Company the right to exercise the Company Purchase Option. 

(3)    Following a Purchase Event, the Purchase Right Members shall have the right, as provided in subsection (b) of
this Section 2, to purchase from the Purchaser or the Purchaser’s personal representative, as the case may be, at the Option Price (as defined herein), the number of Shares determined by the calculation shown on Exhibit A hereto
opposite the heading “Calculation of Shares Subject to Member Purchase Option and Company Purchase Option.” 

(4)    Whenever under this Agreement a determination is to be made as to the number of Shares that are subject to the
Member Purchase Option, if such number so subject would not otherwise be a whole number then such number shall be rounded to the nearest whole number, but customary conventions for successive roundings shall be applied so that in no event shall
rounding result in the total number of Shares, including the portion no longer subject to the Member Purchase Option or the Company Purchase Option, the portion subject to the Member Purchase Option and the Company Purchase Option and the portion
with respect to which the Purchase Right Members have exercised the Member Purchase Option and the Company has exercised the Company Purchase Option, exceeding the original number of Shares subject to such Purchase Options. 

(5)    The Company shall have the right to assign its right to purchase the Shares by reason of exercise of the Company
Purchase Option. The Member Purchase Option shall inure to the benefit of, and be exercisable by, each Purchase Right Member’s executors, administrators, heirs and personal representatives. 

  
 2 

 (6)    The “Option Price” shall equal the price per Share
reflected in the Purchase Price for the number of Shares for which the Option Price is being calculated. 
 (b)    (1)
    Within ten Business Days after a Purchase Event occurs, the Company shall notify the Purchase Right Members of the occurrence of such Purchase Event, which notice shall state the date on which the Purchase Event occurred, the
number of Shares subject to the Member Purchase Option and the Purchaser’s address for purposes of notices under this Agreement. Within 90 days following such Purchase Event, each Purchase Right Member shall notify the Purchaser, if such
Purchase Right Member wishes to exercise his Member Purchase Option. A Purchase Right Member may exercise the Member Purchase Option for all or any part of the Shares that are subject to the Member Purchase Option at the time of the Purchase Event,
and shall state the number of Shares such Purchase Right Member wishes to purchase in his exercise notice. 
 (2)    If
the aggregate number of Shares for which Purchase Right Members exercise the Member Purchase Option is less than or equal to the number of Shares subject to the Member Purchase Option, then each exercising Purchase Right Member shall be entitled and
obligated to purchase the number of Shares stated in his exercise notice. Any remaining Shares subject to the Member Purchase Option and not taken up by exercise of the Member Purchase Option shall be subject to the Company Purchase Option, as
provided in Section 2(c). 
 (3)    If the aggregate number of Shares for which Purchase Right Members exercise
the Member Purchase Option is greater than the number of Shares subject to the Member Purchase Option, then each exercising Purchase Right Member shall be allocated a number of such Shares equal to the lesser of (1) the number of Shares for
which such Purchase Right Member exercised the Member Purchase Option and (2) such Purchase Right Member’s Pro Rata Share of the number of Shares subject to the Member Purchase Option. The remaining Shares not so allocated shall be
allocated among Purchase Right Members who exercised the Member Purchase Option for more than their Pro Rata Share. Each such Purchase Right Member shall be allocated such number of remaining Shares equal to the lesser of (1) the number of
Shares for which such Purchase Right Member exercised the Member Purchase Option in excess of such Purchase Right Member’s Pro Rata Share of the aggregate number of Shares subject to the Member Purchase Option and for which no allocation of
Shares has been made and (2) such Purchase Right Member’s Pro Rata Share of such remaining Shares. The immediately preceding allocation method shall be applied successively until all Shares are allocated among the Purchase Right Members.

 (4)    The term “Pro Rata Share” shall mean at any time with respect to any Purchase Right Member a
fraction the numerator of which is the number of shares of Class 1 Stock of the Company owned by such Purchase Right Member at the time of exercise of the Member Purchase Option by such Purchase Right Member, as such number is shown in the
Company’s Stockholders Ledger, and the denominator of which is the aggregate number of shares of Class 1 Stock owned, at the time of exercise of the Member Purchase Option by the respective

  
 3 

 
Purchase Right Members, by the Purchase Right Members who have validly exercised the Member Purchase Option in connection with the Purchase Event for which the Pro Rata Share is being calculated,
as such number is shown in the Company’s Stockholders Ledger. In case the number of Shares constituting a Purchase Right Member’s Pro Rata Share would otherwise result in a fraction of a Share, such number shall be rounded using customary
rounding conventions for all exercising Purchase Right Members so that no such Purchase Right Member’s Pro Rata Share results in a fraction of a Share and the sum of all exercising Purchase Right Members’ Pro Rata Shares equals the number
of Shares subject to the Member Purchase Option the exercise of which gives rise to the calculation of Pro Rata Shares. 

(c)    If any Shares subject to the Member Purchase Option remain unallocated to Purchase Right Members after application
of Section 2(b), then within 90 days following the Purchase Event the Company shall notify the Purchaser as to whether the Company wishes to purchase all or some of the Shares that are subject to the Company Purchase Option pursuant to exercise
of the Company Purchase Option or that the Company has assigned all or part of the Company Purchase Option to another person who wishes to purchase all or some of such Shares pursuant to exercise of the Company Purchase Option. 

(d)    If any Purchase Right Member or the Company (or its assignee) elects to purchase any Shares hereunder, the Company
shall set a date for the closing of the transaction (the “Option Purchase Closing”) at a place and time specified by the Company or, at the Company’s election exercised by notice in writing to the exercising Purchase Right Members and
to the Purchaser, the Option Purchase Closing may be completed by mail. At the Option Purchase Closing, each purchasing Purchase Right Member and the Company (or its assignee) shall tender payment for the applicable number of Shares to be purchased
pursuant to the Member Purchase Option or Company Purchase Option, as the case may be, calculated based on the applicable Option Price, and the applicable number of Shares so purchased shall be transferred to each purchasing Purchase Right Member
and the Company (or its assignee), respectively. The amount payable by the Company at the Option Purchase Closing shall be payable to the Purchaser, at the election of the Company exercised by notice in writing to the Purchaser, by cancellation of
all or a portion of any outstanding indebtedness of the Purchaser to the Company or in cash or by check, or any combination thereof. The amount payable by a Purchase Right Member or an assignee of the Company shall be payable in cash or by check.

 (e)    The Purchaser hereby pledges and grants a security interest to the Company in the portion of the Shares that,
from time to time, are subject to the Member Purchase Option and the Company Purchase Option, in order to secure the obligation of the Purchaser to transfer to Purchase Right Members and the Company upon exercise of the Member Purchase Option and
the Company Purchase Option, as the case may be, the portion of the Shares that are subject to the Member Purchase Option and the Company Purchase Option. The Company may file financing statements under the Uniform Commercial Code to record such
pledge and security interest. Upon the Company’s request, the Purchaser will promptly execute such financing statements from time to time. The Purchaser hereby constitutes the Company’s Board of Directors (the “Board”), with full
power of substitution, as the Purchaser’s attorney-in-fact for purposes of executing and filing any and all such financing statements on behalf of the Purchaser and
hereby authorizes the Board or its duly appointed officer of the Company to sign such financing statements. 

  
 4 

 3.    Certain Adjustments to the Shares. If, from time to
time during the term of this Agreement: 
 (a)    There is any in-kind dividend,
liquidating distribution payable in securities, membership share split, reverse membership share split, combination or other change in the character or pro rata change in the amount of any of the membership shares of stock of the Company of the same
class as the Shares (or any successor or substitute securities), in any such case which affects the Shares (or any successor or substitute securities); or 

(b)    There is any consolidation or merger of the Company or sale of assets of the Company followed by a dividend,
distribution or other payment to members; or 
 (c)    There is any tender or exchange offer to holders of membership
shares of stock of the Company (or any successor or substitute securities) of the same class as the Shares (or any successor or substitute securities), 

then in each such event, any and all new, substituted or additional securities or other property to which the Purchaser is entitled by reason of the
Purchaser’s ownership of the Shares shall become subject to this Agreement immediately upon the Purchaser becoming entitled thereto and shall be included in the term “Shares” for all purposes with the same force and effect as the
Shares subject to the Member Purchase Option, Company Purchase Option, and other terms of this Agreement are so subject as of the date of this Agreement. While the aggregate Option Price at the time payable upon exercise of the Member Purchase
Option or Company Purchase Option shall remain the same immediately after each such event as the aggregate Option Price immediately before such event, the Option Price payable for each Share and/or other unit of security or property payable upon
exercise of the Member Purchase Option or Company Purchase Option shall be appropriately adjusted as determined by the Board and set forth in a resolution duly adopted by the Board. In case any such substituted or additional securities or other
property is certificated securities, the Company may establish an escrow and require such certificated securities that are subject to the Member Purchase Option or Company Purchase Option to be deposited in such escrow to assure delivery thereof,
free of liens, upon exercise of the Member Purchase Option and Company Purchase Option. The Purchaser shall also sign and deposit in such escrow stock, bond or other powers in blank relating to such additional escrowed securities, as required by the
Company. 
 4.    Restriction on Transfer. (a)     In addition to any
restrictions contained in the LLC Agreement, the Stockholders Agreement, the Registration Rights Agreement or any agreement entered into pursuant to any thereof, the Purchaser shall not sell, transfer, pledge, hypothecate or otherwise dispose of any
of the Shares that remain subject to the Member Purchase Option or the Company Purchase Option, subject only to the exceptions specified in Section 5. Any transfer of such Shares permitted by Section 5 shall be made strictly in accordance
with the terms of this Agreement. 
 (b)    The Purchaser shall not sell, transfer, pledge, hypothecate or otherwise
dispose of any of the Shares, even when made in accordance with Sections 4(a) and 5, except in accordance with the terms of the LLC Agreement, the Stockholders Agreement or the Registration Rights Agreement. 

  
 5 

 5.    Termination of Purchase Options. 

(a)    The provisions of Section 2 and Section 4(a) shall terminate as to the Shares on the closing date of the
earliest of: 
 (1)    the closing of a sale of all or substantially all of the assets of the Company; 

(2)    the closing of a merger, consolidation or similar business combination transaction of the Company pursuant to
which, in exchange for their membership shares of stock in the Company, the members of the Company receive cash, property (other than membership shares of stock in the Company) or shares of stock or other securities of another company and in which
transaction persons who held membership shares of stock in the Company immediately prior to such transaction do not own a majority of the shares of common stock (or equivalent securities) of such other company that are outstanding immediately after
such transaction; or 
 (3)    the purchase by a third party or a Group (as defined herein), including, without
limitation, by way of a tender offer by a third party or Group, of a number of shares of stock of the Company that, together with any shares owned by such person or any member of such Group, entitle the holders together to elect a majority of the
members of the Board, whether purchased in a single transaction or a series of related transactions. 
 As used herein, “Group” shall have the
meaning of such term for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and Regulation 13D-G thereunder. 

(b)    The provisions of Section 2 shall also terminate as to Shares at the time subject to the Member Purchase
Option and Company Purchase Option as stated on Exhibit A. 
 (c)    The restrictions on transfer in
Section 4(a) shall not apply to a transfer of any Shares by the Purchaser, either during the Purchaser’s lifetime or on death by will or intestacy, in any such case to the Purchaser’s ancestors, descendants or spouse; provided,
however, that in each such case a transferee shall receive and hold the transferred Shares subject to the provisions of this Agreement, including, without limitation, Sections 2 and 4 hereof; and provided further, however, that there
shall be no further transfer of such Shares so long as the Shares remain subject to the Member Purchase Option and the Company Purchase Option, other than a transfer pursuant to this Section 5(c). Each such permitted transferee under this
Section 5(c) shall enter into a written agreement with the Company prior to such transfer agreeing to be bound by this Agreement on terms acceptable to the Company. After any such transfer, the expiration or termination of the Member Purchase
Option and Company Purchase Option shall be applied pro rata to Shares held by the Purchaser and Shares held by each permitted transferee. 

(d)    The Company shall not be required (i) to transfer any Shares on its books if such Shares shall have been sold
or transferred in violation of any of the provisions set forth in this Agreement, the LLC Agreement, the Stockholders Agreement, the Registration Rights Agreement or any agreement entered into pursuant to any thereof, or (ii) to treat as owner
of the Shares or to accord any economic or membership rights to vote as such purported transferee or to pay distributions to any such purported transferee to whom all or any part of the Shares shall have been so transferred. 

  
 6 

 (e)    Subject to the other provisions of this Section 5, in the
event of any purported transfer by operation of law or other involuntary transfer (including, but not limited to, transfers by operation of law or other involuntary transfers in connection with a divorce, dissolution, legal separation or annulment)
by the Purchaser or its permitted transferee of all or a portion of the Shares that are subject to the Member Purchase Option or the Company Purchase Option which transfer does not occur in accordance with the other provisions of this
Section 5, the Company shall have the right to purchase all of such Shares transferred at the purchase price paid by the Purchaser pursuant to this Agreement. Upon such a transfer, the persons purporting to transfer or to acquire such Shares
shall promptly notify the Company in writing of such transfer. The right to purchase such Shares shall be provided to the Company during the period from the time of such transfer to the date that is 90 days following receipt by the Company of such
written notice of the transfer. 
 6.    Legends. All certificates, if any, for any of the Shares subject
to the provisions of this Agreement shall have endorsed thereon the following legends: 
 (a)    “THE SHARES
REPRESENTED BY THIS CERTIFICATE ARE SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER AS SET FORTH IN AN AGREEMENT BETWEEN THE COMPANY AND THE MEMBER, A COPY OF WHICH AGREEMENT IS ON FILE AT THE PRINCIPAL OFFICE OF THE COMPANY.” 

(b)    “THESE SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”). THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED OR HYPOTHECATED IN THE ABSENCE OF A REGISTRATION STATEMENT IN EFFECT WITH RESPECT TO THE SECURITIES UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED OR UNLESS SOLD PURSUANT TO RULE 144 OF THE SECURITIES ACT.” 
 (c)    Any legend
required to be placed thereon by applicable blue sky laws of any state. 
 (d)    The Company may also place stop
transfer restrictions in its Stockholders Ledger and give stop transfer instructions to its transfer agent, if any, to give effect to the restrictions arising under this Agreement and applicable law. 

7.    Representations, Warranties, Covenants and Agreements. 

(a)    By the Purchaser. The Purchaser hereby represents and warrants to, and covenants and agrees with, the
Company as follows: 
 (1)    Circumstances of Purchase; Capacity to Protect Interests. The Purchaser is
purchasing the Shares solely for the Purchaser’s own account and not with a view to or for sale in connection with any distribution of the Shares or any portion thereof and not with any present intention of selling, offering to sell or
otherwise disposing of or distributing the Shares 

  
 7 

 
or any portion thereof in any transaction other than a transaction exempt from registration under the Securities Act of 1933, as amended (the “1933 Act”). The entire legal and
beneficial interest in the Shares is being purchased, and will be held, for the Purchaser’s account only, and neither in whole nor in part for any other person. 

(2)    Information Concerning Company; Location. The Purchaser has heretofore had an opportunity to discuss
the offering of the Shares and the Company and its business, plans, operations and financial condition with the Company’s officers and has heretofore received all such information as the Purchaser has deemed necessary and appropriate to enable
the Purchaser to evaluate the financial risks inherent in making an investment in the Shares, and the Purchaser has received satisfactory and complete responses concerning the offering of the shares and the business and financial condition of the
Company to all inquiries in respect thereof; and the Purchaser has received, read and understands the terms of the LLC Agreement, the Stockholders Agreement and the Registration Rights Agreement. The Purchaser’s principal residence or principal
place of business is located at the address set forth on Exhibit A hereto. 
 (3)    Restricted
Securities. The Purchaser understands and acknowledges that: 
 (A)    the sale of the Shares has not been
registered under the 1933 Act, and the Shares must be held indefinitely unless subsequently registered under the 1933 Act and applicable state blue sky laws or an exemption from such registration is available, and the Company is under no obligation
to so register the Shares except as provided in the Registration Rights Agreement; 
 (B)    any certificates for the
Shares will bear the legends specified in, or permitted by, Section 6 hereof; and 
 (C)    the Company will make
a notation in its records and the records of any transfer agent of the aforementioned restrictions on transfer and legends. 

(4)    Disposition under Rule 144. The Purchaser understands that the Shares are restricted securities
within the meaning of Rule 144 promulgated under the 1933 Act; that the exemption from registration under Rule 144 will not be available in any event for at least one year from the date of purchase and payment for the Shares, and even then will not
be available unless (i) a public trading market then exists for shares of Class 1 Stock of the Company, (ii) adequate information concerning the Company is then available to the public, and (iii) other terms and conditions of
Rule 144 are complied with, and that any sale of the Shares under Rule 144 may be made only in limited amounts in accordance with such terms and conditions, subject at all times to the other restrictions on any transfer of the Shares which
restrictions are contained in this Agreement, the LLC Agreement, the Stockholders Agreement or the Registration Rights Agreement. 

(5)    Further Limitations on Disposition. Without in any way limiting the Purchaser’s
representations, warranties, covenants and agreements set forth above, the Purchaser further represents, warrants, covenants and agrees that the Purchaser shall not make any disposition of all or any portion of the Shares unless and until: 

(A)    (i)     There is then in effect a registration statement under the 1933 Act covering such
proposed disposition and such disposition is made in accordance with such registration statement; or 

  
 8 

 (ii)    (x)     the Purchaser shall have notified
the Company of the proposed disposition and shall have furnished the Company with a detailed statement of the circumstances surrounding the proposed disposition, (y) the Purchaser shall have furnished the Company with an opinion of the
Purchaser’s counsel, which opinion shall be satisfactory in form, scope and substance to the Company, to the effect that such disposition will not require registration of the Shares under the 1933 Act, and (z) such opinion of the
Purchaser’s legal counsel shall have been concurred in by legal counsel for the Company and the Company shall have advised the Purchaser of such concurrence; and 

(B)    The Shares that the Purchaser proposes to transfer are no longer subject to the Member Purchase Option or the
Company Purchase Option set forth in Section 2 hereof and the Purchaser shall have complied with the applicable terms of the LLC Agreement, the Stockholders Agreement, the Registration Rights Agreement and any other agreement entered into
pursuant to any thereof. 
 (6)    Other Restrictions. (A)     The Purchaser
shall not sell or otherwise transfer or dispose of any Shares (or capital stock of any successor) for a period specified by the representative of the underwriters of Shares (or other securities) of the Company (or any successor) not to exceed 180
days following the effective date of each public offering of the Company’s (or its successor’s) securities pursuant to a registration statement of the Company (or its successor) filed under the 1933 Act; provided, that such period may be
extended upon the request of the managing underwriter(s) to the extent required by any rules of the Financial Industry Regulatory Authority for an additional period of up to 15 days if the Company (or its successor) issues or proposes to issue an
earnings or other public release within 15 days of the expiration of such period. The Purchaser agrees to execute and deliver such other agreements as may be reasonably requested by the Company (or its successor) or the underwriter(s) that are
consistent with the foregoing or which are necessary or appropriate to give further effect thereto. In addition, if requested by the Company (or its successor) or the representative of the underwriters of Shares (or other securities) of the Company
(or its successor), the Purchaser shall immediately provide, within ten days of such request, such information as may be required by the Company (or its successor’s) or such representative in connection with the completion of any public
offering of the Company’s (or its successor’s) securities pursuant to a registration statement filed under the 1933 Act. The obligations described in this Section 7(f) shall not apply to a registration relating solely to employee
benefit plans on a Registration Statement or Form S-8 or similar forms that may be promulgated by the Securities and Exchange Commission (the “SEC”) in the future, or a registration relating solely
to a transaction covered by a Registration Statement on Form S-4 under Rule 145 as promulgated by the SEC or similar forms that may be promulgated by the SEC in the future. The Company (or its successor) may
impose stop-transfer instructions with respect to the Shares (or other securities) subject to the foregoing restriction until the end of such market standoff period. 

(B)    In connection with any underwritten public offering of equity interests in the Company or equity securities of any
successor, the Purchaser shall, 

  
 9 

 
immediately upon request of the Company, enter into such further restrictions on resale of the Shares or any other securities issued or exchanged directly or indirectly in respect of the Shares
as the Company (or its successor) and any underwriter(s) for such offering may reasonably request in order to facilitate the offer, sale and distribution of equity interests in the Company or any successor in connection with such offering so long as
the terms of such restrictions are substantially the same as those required of other persons who are or were members of the Company who are subject to restrictions similar to this Section 7(a)(6). 

(C)    The Purchaser will, immediately upon request of the Company (or its successor), also execute and deliver with
respect to the Shares or such other securities any stockholders or equity holders agreement, voting agreement, investor rights agreement or similar agreement from time to time approved by the Board or the board of directors or similar body of the
Company’s successor. 
 (7)    Valuation of Shares. (A)     The Purchaser
understands that the Company has not appraised the value of the Shares and that the responsibility for valuing the Shares for purposes of the Purchaser’s income taxes rests solely with the Purchaser. The Purchaser understands that the Company
can give no assurances that the Purchase Price is the fair market value of the Shares and that it is possible that, with the benefit of hindsight, the Internal Revenue Service (the “I.R.S.”) might successfully assert that the value of the
Shares on the Closing Date is greater than the Purchase Price. 
 (B)    If the I.R.S. were to succeed in a
determination for federal income tax purposes that the Shares have value greater than that upon which the sale thereof hereunder was based, the additional value would constitute ordinary income as of the date of its receipt (or, in the case of
Shares subject to restrictions, as of the date the restrictions lapse if the Purchaser does not make an election as provided in Section 7(h)). The additional taxes (and interest) due would be payable by the Purchaser, the Company has no
obligation to reimburse the Purchaser for the tax liability, and the Purchaser assumes all responsibility for such potential tax liability. If such additional value represents more than 25 percent of the Purchaser’s gross income for the
year in which the value of the Shares was taxable, the I.R.S. would have six years from the due date for filing the return (or the actual filing date of the return if filed thereafter) within which to assess the Purchaser the additional tax and
interest which would then be due. The Purchaser understands that additional tax consequences could arise under applicable state and local laws. The Purchaser understands and agrees that the Purchaser must rely on its own tax advisers and not on the
Company, and that the information in this Agreement and any other statements or information made to the Purchaser as to tax aspects of the purchase of the Shares is for information only, and shall not constitute tax advice by the Company or its
professional advisors to the Purchaser. 
 (8)    Section 83(b)
Election. The Purchaser understands that section 83 of the Internal Revenue Code of 1986, as amended (the “Code”), taxes as ordinary income the difference between the amount paid for the Shares and the fair market value of the
Shares as of the date any restrictions on the Shares lapse. In this context, “restriction” means the right of other members of the Company or of the Company to buy the Shares pursuant to the Member Purchase Option and the Company Purchase
Option, other than any such restrictions that by their terms never lapse. The Purchaser agrees to elect to be taxed at the time the Purchaser purchases the 

  
 10 

 
Shares, rather than when and as the Member Purchase Option and the Company Purchase Option restrictions lapse, by filing an election under section 83(b) of the Code with the I.R.S. within 30 days
after the Closing Date. Even if the fair market value of the Shares equals the amount paid for the Shares, the election must be made so that any subsequent increase in the value of the Shares prior to the lapse of restrictions will not be taxed as
ordinary income. A form for making this election is attached hereto as Exhibit B. The Purchaser understands that failure to make this filing timely could result in the recognition of additional ordinary income by the Purchaser, as the Member
Purchase Option and the Company Purchase Option lapse, on the amount, if any, by which the fair market value of the Shares (or a portion thereof) at the time such restrictions lapse exceeds the portion of the Purchase Price paid for such Shares. The
Purchaser also understands that any income recognized as a result of a section 83(b) election will not give rise to an offsetting deduction in the event of a subsequent forfeiture resulting from the restrictions or a decline in the value of the
Shares. 
 THE PURCHASER ACKNOWLEDGES THAT IT IS THE PURCHASER’S SOLE RESPONSIBILITY, AND NOT THE COMPANY’S, TO FILE TIMELY THE
ELECTION UNDER SECTION 83(b) OF THE CODE, EVEN IF THE PURCHASER REQUESTS THE COMPANY OR ITS REPRESENTATIVES TO MAKE THIS FILING ON THE PURCHASER’S BEHALF. 

(9)    Withholding Taxes. At the time the Purchaser purchases the Shares and upon each lapse of the Member
Purchase Option and the Company Purchase Option, the Purchaser shall be required, if applicable, to pay to the Company in cash (or make other arrangements for satisfaction of) any taxes of any kind required by law to be withheld with respect to such
Shares, all on terms satisfactory to the Company. The Company shall have the right to deduct any such taxes from any payment of any kind otherwise due to the Purchaser and shall not be obligated remove the Shares from the terms of this Agreement or
recognize any purported transfer thereof until the Purchaser pays or makes provision for such taxes, satisfactory to the Company. 

(10)    Additional Terms and Provisions. The Purchaser also makes the representations, warranties,
covenants and agreements, if any, as set forth under the heading “Additional Terms and Provisions” on Exhibit A hereto. 

(b)    By the Company. The Company hereby represents and warrants to, and covenants and agrees with, the
Purchaser as follows: 
 (1)    Organization and Corporate Power. The Company is a limited liability
company duly formed, validly existing and in good standing under the laws of the State of Delaware. The Company has all requisite corporate power and authority to enter into and perform this Agreement, the LLC Agreement, the Stockholders Agreement
and the Registration Rights Agreement and generally to carry out the transactions contemplated hereby and thereby. 

(2)    Authorization. (A)    Prior to the Closing, this Agreement, the LLC Agreement,
the Stockholders Agreement and the Registration Rights Agreement and all other documents and instruments executed or to be executed by the Company in connection herewith and therewith will have been duly authorized, this Agreement has been duly
executed and 

  
 11 

 
delivered by the Company and constitutes, and the Stockholders Agreement and the Registration Rights Agreement, when executed and delivered by the Company will constitute, the legal, valid and
binding obligations of the Company, enforceable in accordance with their respective terms except as limited by applicable bankruptcy, insolvency and similar creditors’ rights laws and except that equitable remedies may be unavailable, whether
sough in a proceeding at law or in equity. Prior to the Closing, the execution, delivery and performance of this Agreement, the LLC Agreement, the Stockholders Agreement and the Registration Rights Agreement, and the issuance, sale and delivery of
the Shares will have been duly authorized by all necessary corporate or other action of the Company. 
 (B)    At the
time of the Closing, no further approval or authorization of the members of the Company or the Board or of any governmental authority will be required for the issuance and sale of the Shares. Except as provided in the LLC Agreement, this Agreement
and the Restricted Stock Agreements by and between the Company and the Purchase Right Members, no member of the Company or any other Person is entitled to any preemptive or similar rights with respect to the purchase or sale of any securities by the
Company. When issued and sold to the Purchaser, the Shares shall be duly and validly issued, with no personal liability attaching to the ownership thereof and the Shares shall have the rights as set forth in the LLC Agreement. There are no
restrictions on the transfer of shares of stock of the Company other than those imposed by relevant federal and state securities laws and as otherwise contemplated by this Agreement and as otherwise provided in the LLC Agreement, the Stockholders
Agreement and the Registration Rights Agreement. The offer and sale of all capital stock and other securities of the Company issued before the Closing in offerings of securities complied with or were exempt from all applicable federal and state
securities laws and no member has a right of rescission or damages with respect thereto. No holder of any securities of the Company is entitled to any alteration of the terms or the amount of such securities by reason of the issuance of the Shares.

 (3)    Compliance with Other Instruments. The Company is in compliance in all material respects with
the terms and provisions of the LLC Agreement. The execution, delivery and performance by the Company of this Agreement, the Stockholders Agreement and the Registration Rights Agreement and the other agreements and transactions contemplated hereby
and thereby will not conflict with or result in any default under any material contract, obligation or commitment of the Company or any provision of the LLC Agreement, or corporate restriction of the Company, or the creation of any encumbrance upon
any of the properties or assets of the Company, except pursuant to this Agreement. The Company’s execution and delivery of this Agreement, the Stockholders Agreement and the Registration Rights Agreement and its performance of the transactions
contemplated hereby and thereby will not violate any material instrument, agreement, judgment, or decree, order, statute, rule or regulation of any governmental authority applicable to the Company. No consent, approval or authorization of, or
declaration, filing or registration with, any governmental authority is required to be made or obtained by the Company in connection with its execution or delivery of this Agreement, the Stockholders Agreement and the Registration Rights Agreement,
the performance by the Company of its obligations hereunder and thereunder or the consummation of the transactions contemplated hereby or thereby. 

  
 12 

 (4)    Offerees. Neither the Company nor anyone acting on
its behalf has in the past or will hereafter sell, offer for sale or solicit offers to buy any securities of the Company so as to bring the offer, issuance or sale of the Shares to the Purchaser, as contemplated by this Agreement, within the
provisions of Section 5 of the 1933 Act. 
 8.    Limitation on Payments. 

(a)    Payments Limitation. If the severance and other benefits provided for in this Agreement or otherwise
payable to the Purchaser (i) constitute “parachute payments” within the meaning of section 280G of the Code, and (ii) would be subject to the excise tax imposed by section 4999 of the Code (the “Excise Tax”), then the
Purchaser’s benefits under this Agreement shall be either: 
 (1)    delivered in full, or 

(2)    delivered to such lesser extent that would result in no portion of such benefits being subject to the Excise Tax,

 whichever of the foregoing amounts, taking into account the applicable federal, state and local income taxes and the Excise Tax, results in the receipt
by the Purchaser on an after-tax basis, of the greatest amount of benefits, notwithstanding that all or some portion of such benefits may be taxable under section 4999 of the Code. Any reduction in payments
and/or benefits required by this Section 8 will occur in the following order: (1) reduction of cash payments; (2) reduction of vesting acceleration of equity awards; and (3) reduction of other benefits paid or provided to the
Purchaser. If acceleration of vesting of equity awards is to be reduced, such acceleration of vesting will be cancelled in the reverse order of the date of grant for the Purchaser’s equity awards. If two or more equity awards are granted on the
same date, each award will be reduced on a pro-rata basis. In no event will the Purchaser exercise any discretion with respect to the ordering of any reductions of payments or benefits under this
Section 8. 
 (b)    Determination. Unless the Company and the Purchaser otherwise agree in writing,
any determination required under this Section 8 shall be made in writing by the Company’s independent public accountants or a nationally recognized accounting firm selected by the Company (the “Accountants”), whose determination
shall be conclusive and binding upon the Purchaser and the Company for all purposes. For purposes of making the calculations required by this Section 8, the Accountants may make reasonable assumptions and approximations concerning applicable
taxes and may rely on reasonable, good faith interpretations concerning the application of sections 280G and 4999 of the Code. The Company and the Purchaser shall furnish to the Accountants such information and documents as the Accountants may
reasonably request in order to make a determination under this Section 8. The Company shall bear all costs the Accountants may reasonably incur in connection with any calculations contemplated by this Section 8. 

9.    Miscellaneous. 

(a)    Rights as Member. Subject to the provisions and limitations hereof and of the LLC Agreement, the
Stockholders Agreement and the Registration Rights Agreement, the Purchaser may, during the term of this Agreement, exercise all rights and privileges of a Class 1 Member of the Company with respect to the Shares, to the extent the Purchaser
continues to hold the Shares as shown by the LLC Agreement. 

  
 13 

 (b)    Further Assurances. The Purchaser agrees to execute
such further instruments and to take such further action as may reasonably be requested by the Company to carry out the intent of this Agreement. 

(c)    Notices. Any notice required or permitted hereunder shall be given in writing and shall be deemed
effectively given upon personal delivery, on the date of delivery if sent by nationally recognized overnight delivery service with written or electronic confirmation of delivery, or three days after deposit in the facilities of the United States
Postal Service, by certified mail with postage and fees prepaid, addressed to the Purchaser at the Purchaser’s address shown on Exhibit A hereto and to the Company at the address of its principal corporate offices (attention: Chief
Executive Officer) or at such other address as such party may designate by ten days’ advance written notice to the other party hereto. 

(d)    Successors and Assigns. The Company may assign its rights and delegate its duties under this
Agreement, including, without limitation, Section 2 and the Company Purchase Option and Section 4. This Agreement shall inure to the benefit of and be binding on the successors and the assigns of the Company and, subject to the
restrictions on transfer herein set forth, inure to the benefit of and be binding on the Purchaser and the Purchaser’s heirs, executors, administrators, successors and permitted assigns. The Purchase Right Members are express third party
beneficiaries of this Agreement with respect to the Member Purchase Option and all related provisions hereof; provided, however, that the Company and the Purchaser may at any time or from time to time amend, modify or waive any provision
hereof without the consent or approval of the Purchase Right Members. There are no other third party beneficiaries. 

(e)    Direction to Transfer Shares. The Purchaser hereby authorizes and directs the Board to transfer the
respective Shares as to which the Member Purchase Option or Company Purchase Option has been exercised from the Purchaser to Purchase Right Members, the Company or its assignees in accordance with the exercise of such options. 

(f)    No Right to Employment, Consulting or Other Position. Nothing in this Agreement shall affect in any
manner whatsoever the right or power of the Company, or a parent or subsidiary of the Company, to terminate the Purchaser’s relationship with the Company as a director, officer, employee, consultant, or otherwise, for any reason or for no
reason, with or without cause, and the Purchaser shall not, by reason of this Agreement, have any right or claim to employment or continued employment or any other relationship with the Company. 

(g)    Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
State of Delaware applicable to contracts to be performed in the State of Delaware. 
 (h)    Counterparts.
This Agreement may be executed in any number of counterparts and by different parties hereto on separate counterparts, each of which counterparts when so executed and delivered, shall be deemed to be an original and all of which
counterparts, taken together, shall constitute but one and the same instrument. 

  
 14 

 (i)    Headings. Section and paragraph headings in this
Agreement are included herein for convenience of reference only and shall not constitute a part of this Agreement for any other purpose. Capitalized terms used in this Agreement and defined in the introductory paragraph of, or recitals to, this
Agreement shall have the respective meanings provided therein. 
 (j)    Severability. Any provision of
this Agreement that is prohibited, unenforceable or not authorized in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition, unenforceability or nonauthorization without invalidating the remaining
provisions hereof or affecting the validity, enforceability or legality of such provision in any other jurisdiction. 

(k)    Amendments and Waivers. No amendment or waiver of any provision of this Agreement shall in any event
be effective unless the same shall be in writing and signed by the party to be charged with enforcement thereof, and any such waiver shall be effective only in the specific instance and for the specific purpose for which given. No failure on the
part of a party to exercise, and no delay in exercising, any right under this Agreement shall operate as a waiver thereof. No single or partial exercise of any right under this Agreement shall preclude any other or further exercise thereof or the
exercise of any other right. 
 (l)    Entire Agreement. This Agreement, including the exhibits hereto,
the LLC Agreement, the Stockholders Agreement, the Registration Rights Agreement and any other agreement listed on Exhibit A hereto constitute the entire agreement between the parties with respect to the subject matter hereof. There are no
other written, verbal, express, or implied agreements, understandings, or representations between the parties with respect to the subject matter hereof, except as expressly set forth in this Agreement. The recitals to this Agreement form part of
this Agreement. 
 (m)    Dispute Resolution. 

(1)    General. The parties agree that any and all disputes, claims or controversies arising out of or
relating to this Agreement shall be addressed in good faith negotiations under Section 9(m)(2), and if the matter is not resolved through such negotiations, then on the initiative of any party it shall be submitted to JAMS, or its successor,
for mediation in the Borough of Manhattan, New York New York pursuant to Section 9(m)(3), and if the matter is not resolved through such mediation, then on the initiative of any party it shall be submitted for final and binding arbitration
pursuant to Section 9(m)(4). 
 (2)    Good Faith Negotiations. (A)    The
parties shall attempt in good faith to resolve any dispute, claim or controversy arising out of or relating to this Agreement promptly by negotiation between them. In the case of any party that is a company, the representative of such company in
such negotiation shall be an executive who has authority to settle the controversy and who is at a higher level of management than the persons at such company who have direct responsibility for administration of this Agreement. Either party may give
the other party written notice of any dispute not resolved in the normal course of business. Within 15 days after delivery of the notice, the receiving party shall submit to the other a written response. The notice and response shall include with
reasonable particularity (a) a statement of each party’s position and a summary of arguments supporting that position, and (b) in the case of a company, 

  
 15 

 
the name and title of the executive who will represent that party and of any other person who will accompany such party. Within 30 days after delivery of the notice, the parties to such dispute
shall meet at a mutually acceptable time and place. 
 (B)    Unless otherwise agreed in writing by the negotiating
parties, the above-described negotiation shall end at the close of the first meeting of the parties described above (the “First Meeting”). The closing of the First Meeting shall not preclude continuing or later negotiations, if desired.

 (C)    All offers, promises, conduct and statements, whether oral or written, made in the course of the negotiation
under this Section 9(m)(2) by any of the parties, their agents, employees, experts and attorneys are confidential, privileged and inadmissible for any purpose, including impeachment, in arbitration or other proceeding involving the parties,
provided that evidence that is otherwise admissible or discoverable shall not be rendered inadmissible or non-discoverable as a result of its use in the negotiation. 

(D)    At no time prior to the First Meeting shall either side initiate a mediation, arbitration or litigation related to
this Agreement, except to pursue a provisional remedy that is authorized by law or by the arbitration rules applicable under Section 9(m)(4) or by agreement of the parties. This limitation is inapplicable to a party with respect to another
party who fails to comply with the requirements of Section 9(m)(2) within ten days after notice by one party to such non-complying party of such non-compliance.

 (5)    All applicable statutes of limitation and defenses based upon the passage of time shall be tolled while the
procedures specified in Sections 9(m)(2)(A) and 9(m)(2)(B) are pending and for 15 calendar days thereafter. The parties will take such action, if any, required to effectuate such tolling. 

(6)    If the matter is not resolved by negotiation pursuant to this Section 9(m)(2), then any party may proceed to
mediation of the matter as provided in Section 9(m)(3). 
 (3)    Mediation.
(A)    Any party may commence mediation by providing to JAMS and the other party or parties to such dispute, claim or controversy a written request for mediation at a time when permitted by this Section 9(m), which
request shall set forth the subject of the dispute, claim or controversy and the relief requested. 
 (B)    The
parties will cooperate with JAMS and with one another in selecting a mediator from the JAMS panel of neutrals and in scheduling the mediation proceedings. The parties agree that they will participate in the mediation in good faith and that they will
share equally in its costs. 
 (C)    All offers, promises, conduct and statements, whether oral or written, made in
the course of the mediation by any of the parties, their agents, employees, experts and attorneys, and by the mediator or any JAMS employees, shall be confidential, privileged and inadmissible for any purpose, including impeachment, in any
arbitration or other proceeding involving the parties, provided that evidence that is otherwise admissible or discoverable shall not be rendered inadmissible or non-discoverable as a result of its use in the
mediation. 

  
 16 

 (D)    Any party involved in a mediation may initiate arbitration with
respect to the matters submitted to mediation by filing a written demand for arbitration at any time following the initial mediation session or at any time following 45 days from the date of filing the written request for mediation, whichever occurs
first (the “Earliest Initiation Date”). The mediation may continue after the commencement of arbitration if the parties so desire. 

(E)    At no time prior to the Earliest Initiation Date shall a party involved in a mediation initiate an arbitration or
litigation related to this Agreement except to pursue a provisional remedy that is authorized by applicable law or by JAMS Rules or by agreement of the parties. This limitation is inapplicable to a party with respect to an arbitration or litigation
against another party who fails to comply with the requirements of Section 9(m)(3)(B) within ten days after notice by any other party to such non-complying party of such
non-compliance. 
 (F)    All applicable statutes of limitation and defenses
based upon the passage of time shall be tolled until 15 days after the Earliest Initiation Date. The parties will take such action, if any, required to effectuate such tolling. 

(4)    Binding Arbitration. (A)    The parties agree that any and all disputes, claims
or controversies arising out of or relating to this Agreement that are not resolved by good faith negotiations under Section 9(m)(2) or mediation under Section 9(m)(3) shall be submitted for final and binding arbitration pursuant to this
Section 9(m)(4) in any forum and form agreed upon by the parties or, in the absence of such an agreement, before a panel of three arbitrators under the auspices of the American Arbitration Association (the “AAA”) in the Borough of
Manhattan, New York, New York in accordance with the Commercial Arbitration Rules of the AAA, including, but not limited to, the rules and procedures applicable to the selection of arbitrators. 

(B)    The arbitrators shall be selected in accordance with the Commercial Arbitration Rules of the AAA. Any arbitrators
selected shall have expertise in business ownership and management and employment and consulting matters in the human drug industry. 

(C)    Any party may initiate an arbitration by providing to AAA and the other party or parties to such dispute, claim or
controversy a written request for arbitration at a time when permitted by this Section 9(m), which request shall set forth the subject of the dispute, claim or controversy and the relief requested. 

(D)    The parties will cooperate with the AAA and with one another in the selection of arbitrators and in scheduling the
arbitration proceedings. The parties agree that they will participate in the arbitration in good faith and that they will share equally in its costs. 

(E)    All offers, promises, conduct and statements, whether oral or written, made in the course of the arbitration by
any of the parties, their agents, employees, experts and attorneys, and by the arbitrators or any AAA employees, are confidential, privileged and inadmissible for any purpose, including impeachment, in any arbitration or other proceeding involving
the parties, provided that evidence that is otherwise admissible or discoverable shall not be rendered inadmissible or non-discoverable as a result of its use in the arbitration. 

  
 17 

 Judgment upon the award rendered by the arbitrators may be entered in any court having
jurisdiction thereof. 
 [signature page follows] 

  
 18 

 IN WITNESS WHEREOF, the parties hereto have duly executed this Agreement, or caused
this Agreement to be duly executed by an officer or other representative thereunto duly authorized, as of the day and year first above written. 
  

			
	INOZYME PHARMA, LLC
		
	By:	 	
                     
                                        

	
	
                    

  

[SIGNATURE PAGE TO RESTRICTED STOCK AGREEMENT]

 
			
		 	Exhibit A
		 	to
		 	Restricted Stock
		 	Agreement

 INOZYME PHARMA, LLC 
  

			
	Name of Purchaser:	  	Axel Bolte
		
	Date of Agreement:	  	[                    ]
		
	Address:	  	[                    ]
		
	Number of Shares:	  	[                    ] shares of Class 1 Stock
		
	Purchase Price:	  	$[        ]
		
	Other Consideration:	  	None
		
	Calculation Date:	  	[                    ]
		
	Closing Location: 	  	 Pusch & Gal
 [Address]

		
	Offices/Positions:	  	[                    ]
		
	Purchase Events:	  	(1) The Purchaser resigns from all of the Offices/Positions without the Company’s consent, other than by reason of death or being Disabled; or
		
		  	(2) The Company terminates the Purchaser from all of the Offices/Positions for Cause.
		
		  	As used in this Exhibit A, “Cause” shall mean:
		
		  	(i) the Purchaser’s repeated failure, in the reasonable judgment of the Board, substantially to perform his or her assigned duties or responsibilities as a service provider in the Offices/Positions, other than as a member of
the Board, as directed or assigned by the Board or the Company’s Chairman of the Board (other than a failure resulting from the Purchaser’s being disabled), after written notice thereof from the Board to the Purchaser describing in
reasonable detail the Purchaser’s failure to perform such duties or responsibilities and the Purchaser having had the

  
 A-1 

			
		  	opportunity to address the Board, with counsel, regarding such alleged failures and his or her failure to remedy same within 30 days of receiving written notice;
		
		  	(ii) the Purchaser engaging in knowing and intentional illegal conduct that was or is materially injurious to the Company or its affiliates;
		
		  	(iii) the Purchaser’s willful violation of a federal or state law or regulation directly or indirectly applicable to the business of the Company or its affiliates, which violation was or is reasonably likely to be injurious to
the Company or its affiliates;
		
		  	(iv) the Purchaser’s willful and material breach of the terms of any confidentiality agreement or invention assignment agreement between the Purchaser and the Company (or any affiliate of the Company);
		
		  	(v) the Purchaser being convicted of, or entering a plea of nolo contendere to, a felony or committing any act of moral turpitude, dishonesty or fraud against, or the misappropriation of material property belonging to, the
Company or its affiliates; or
		
		  	(vi) to the extent so provided in any employment or consulting agreement between the Company and the Purchaser, any event or circumstance that constitutes “cause” for purposes of such agreement.
		
		  	For purposes of this definition, no act or failure to act on the part of the Purchaser shall be deemed “willful” unless done, or omitted to be done, by the Purchaser not in good faith or without reasonable belief that the
action or omission was in, or not opposed to, the best interests of the Company.
		
	Calculation of Shares Subject to Member Purchase Option and Company Purchase Option:	  	The total number of Shares that the Purchase Right Members may purchase upon exercise of the Member Purchase Option and that the Company may purchase upon exercise of the Company Purchase Option based on a Purchase Event shall be
the product obtained by multiplying the number of Shares originally purchased under this Agreement by

  
 A-2 

			
		  	a fraction, the numerator of which shall be a number equal to 36 minus the total number of full calendar months elapsed after the “Calculation Date” specified on this Exhibit A to the date of the Purchase Event, and
the denominator of which shall be 36.
		
	Purchase Right Members:	  	Name
		
		  	 Demetrios Braddock
 Enrique De La Cruz

Joseph Schlessinger
 Chautauqua Corporate Services,
LLC

		
	Termination of Purchase Option:	  	The provision of Section 2 shall terminate as to the Shares at the time subject to the Member Purchase Option and the Company Purchase Option if at or prior to the time of the event or circumstance specified under this heading
no Purchase Event shall have occurred, and
		
		  	(1) the Purchaser’s continuous status as a service provider in all the Offices/Positions terminates due to his death or because he becomes Disabled;
		
		  	(2) the Purchaser’s continuous status as a service provider in any of the Offices/Positions terminates due to his discharge by the Company without Cause;
		
		  	(3) the Purchaser shall cease to serve as a member of the Board due to his removal without cause or because members of the Company fail to re-elect him; or
		
		  	(4) the Purchaser’s continuous status as a service provider in any of the Offices/Positions terminates due to his resignation for “Good Reason” as defined in any employment or consulting agreement between the Company
and the Purchaser that is in effect at such time.
		
		  	For purposes of this Exhibit A a person shall be “Disabled” if he or she has a physical or mental

  
 A-3 

			
		  	illness or condition that renders such person unable in any substantial or material respect to perform such person’s material responsibilities in the applicable Offices/Positions for a period of 90 days, whether or not
consecutive, in any period of 365 consecutive days.
		
	Additional Terms and Provisions:	  	None

  
 A-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]